It was reported that a 5-amino acid peptide Ala-Pro-Arg-Pro-Gly （APRPG） could specifically bind to the tumor angiogenic site. We investigated the antitumor efficacy of doxorubicin （DOX） encapsulated in APRPG modif...It was reported that a 5-amino acid peptide Ala-Pro-Arg-Pro-Gly （APRPG） could specifically bind to the tumor angiogenic site. We investigated the antitumor efficacy of doxorubicin （DOX） encapsulated in APRPG modified liposome （APRPG-LP） compared with DOX encapsulated in non-APRPG modified liposomes （LP） and DOX solution （flee DOX） on Lewis lung carcinoma （LLC） bearing mice. APRPG-LP could efficiently suppress the tumor growth of the experimental mice, compared with LP （P〈0.001）, free DOX （P〈0.001） and saline of negative control （P〈0.001）. The present results demonstrated that the APRPG modified liposomes exhibited a much better therapeutic efficacy over the non-modified liposomes and the DOX solution, because of the effect of targeted tumor angiogenesis disruption. Thus, APRPG-LP could be a promising active-targeting drug carrier to tumor angiogenic site.展开更多
基金National Natural Science Foundation of China (Grant No.30772665)Beijing Nature Science Foundation(Grant No.7083111).
文摘It was reported that a 5-amino acid peptide Ala-Pro-Arg-Pro-Gly （APRPG） could specifically bind to the tumor angiogenic site. We investigated the antitumor efficacy of doxorubicin （DOX） encapsulated in APRPG modified liposome （APRPG-LP） compared with DOX encapsulated in non-APRPG modified liposomes （LP） and DOX solution （flee DOX） on Lewis lung carcinoma （LLC） bearing mice. APRPG-LP could efficiently suppress the tumor growth of the experimental mice, compared with LP （P〈0.001）, free DOX （P〈0.001） and saline of negative control （P〈0.001）. The present results demonstrated that the APRPG modified liposomes exhibited a much better therapeutic efficacy over the non-modified liposomes and the DOX solution, because of the effect of targeted tumor angiogenesis disruption. Thus, APRPG-LP could be a promising active-targeting drug carrier to tumor angiogenic site.
